Highlights
- Market Cap
- $145.40M
- Enterprise Value
- $105.99M
- EPS (TTM)
- -$1.03
- Total Revenue (TTM)
- $26.08M
- Gross Profit (TTM)
- $24.93M
- EBITDA (TTM)
- -$56.30M
- Year Range
- $1.23 - $3.82
- ROA (TTM)
- -69.37%
- ROE (TTM)
- -80.44%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Connect Biopharma Holdings Limited, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Connect Biopharma Holdings Limited
- 1D
- -9.66%
- 1M
- 6.07%
- YTD
- -7.09%
- 6M
- 73.51%
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Sep 3, 2025, CNTB's average daily return is +0.39%, while the average monthly return is +6.84%. At this rate, your investment would double in approximately 0.9 years.
Historically, 71% of months were positive and 29% were negative. The best month was Nov 2025 with a return of +64.3%, while the worst month was Sep 2025 at -24.1%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 1 months.
On a daily basis, CNTB closed higher 48% of trading days. The best single day was Nov 14, 2025 with a return of +26.2%, while the worst single day was Sep 29, 2025 at -16.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.89% | 2.92% | 6.07% | -7.09% | |||||||||
| 2025 | -24.12% | 13.25% | 64.33% | 0.36% | 41.71% |
Benchmark Metrics
Connect Biopharma Holdings Limited has an annualized alpha of 163.85%, beta of 0.07, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since September 04, 2025.
- This stock captured 296.48% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -202.00%) — a profile typical of hedging or uncorrelated assets.
- Beta of 0.07 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 163.85%
- Beta
- 0.07
- R²
- 0.00
- Upside Capture
- 296.48%
- Downside Capture
- -202.00%
Return for Risk
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Connect Biopharma Holdings Limited (CNTB) and compare them to a chosen benchmark (S&P 500 Index).
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Connect Biopharma Holdings Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Connect Biopharma Holdings Limited was 33.81%, occurring on Sep 29, 2025. Recovery took 34 trading sessions.
The current Connect Biopharma Holdings Limited drawdown is 29.00%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -33.81% | Sep 4, 2025 | 18 | Sep 29, 2025 | 34 | Nov 14, 2025 | 52 |
| -32.7% | Nov 21, 2025 | 34 | Jan 12, 2026 | 50 | Mar 25, 2026 | 84 |
| -29% | Mar 27, 2026 | 3 | Mar 31, 2026 | — | — | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Connect Biopharma Holdings Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Connect Biopharma Holdings Limited is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CNTB relative to other companies in the Biotechnology industry. Currently, CNTB has a P/S ratio of 5.6. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CNTB in comparison with other companies in the Biotechnology industry. Currently, CNTB has a P/B value of 2.0. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |